RT Generic
T1 Genomics and Susceptibility Profiles of Extensively Drug-Resistant Pseudomonas aeruginosa Isolates from Spain (vol 61, e01589-17, 2017)
A1 del Barrio-Tofino, Ester
A1 Lopez-Causape, Carla
A1 Cabot, Gabriel
A1 Rivera, Alba
A1 Benito, Natividad
A1 Segura, Concepcion
A1 Milagro Montero, Maria
A1 Sorli, Luisa
A1 Tubau, Fe
A1 Gomez-Zorrilla, Silvia
A1 Tormo, Nuria
A1 Dura-Navarro, Raquel
A1 Viedma, Esther
A1 Resino-Foz, Elena
A1 Fernandez-Martinez, Marta
A1 Gonzalez-Rico, Claudia
A1 Alejo-Cancho, Izaskun
A1 Antonio Martinez, Jose
A1 Labayru-Echverria, Cristina
A1 Duenas, Carlos
A1 Ayestaran, Ignacio
A1 Zamorano, Laura
A1 Martinez-Martinez, Luis
A1 Pablo Horcajada, Juan
A1 Oliver, Antonio
AB This study assessed the molecular epidemiology, resistance mechanisms,and susceptibility profiles of a collection of 150 extensively drug-resistant (XDR) Pseudomonas aeruginosa clinical isolates obtained from a 2015 Spanish multicenter study, with a particular focus on resistome analysis in relation to ceftolozane-tazobactam sus ceptibility. Broth microdilution MICs revealed that nearly all ( 95%) of the isolates were nonsusceptible to piperacillin-tazobactam, ceftazidime, cefepime, aztreonam, imipenem,meropenem, and ciprofloxacin. Most of them were also resistant to tobramycin (77%), whereas nonsusceptibility rates were lower for ceftolozane-tazobactam (31%), amikacin (7%), and colistin (2%). Pulsed-field gel electrophoresis–multilocus sequence typing (PFGE-MLST) analysis revealed that nearly all of the isolates belonged to previously de scribed high-risk clones. Sequence type 175 (ST175) was detected in all 9 participating hospitals and accounted for 68% (n   101) of the XDR isolates, distantly followed by ST244 (n 16), ST253 (n   12), ST235 (n   8), and ST111 (n   2), which were detected only in 1 to 2 hospitals. Through phenotypic and molecular methods, the presence of horizontally acquired carbapenemases was detected in 21% of the isolates, mostly VIM(17%) and GES enzymes (4%). At least two representative isolates from each clone and hospital (n- 44) were fully sequenced on an Illumina MiSeq. Classical mutational mech anisms, such as those leading to the overexpression of the b-lactamase AmpC or efflux pumps, OprD inactivation, and/or quinolone resistance-determining regions (QRDR) mu tations, were confirmed in most isolates and correlated well with the resistance phenotypes in the absence of horizontally acquired determinants. Ceftolozane-tazobactam re sistance was not detected in carbapenemase-negative isolates, in agreement with sequencing data showing the absence of ampC mutations. The unique set of mutations responsible for the XDR phenotype of ST175 clone documented 7 years earlier were found to be conserved, denoting the long-term persistence of this specific XDR lineage n Spanish hospitals. Finally, other potentially relevant mutations were evidenced, includ ing those in penicillin-binding protein 3 (PBP3), which is involved in  -lactam (including ceftolozane-tazobactam) resistance, and FusA1, which is linked to aminoglycoside resis tance.
PB American Society for Microbiology
SN 0066-4804
YR 2017
FD 2017-08-27
LK http://hdl.handle.net/10668/19013
UL http://hdl.handle.net/10668/19013
LA en
NO Del Barrio-Tofiño E, López-Causapé C, Cabot G, Rivera A, Benito N, Segura C, et al. Genomics and Susceptibility Profiles of Extensively Drug-Resistant Pseudomonas aeruginosa Isolates from Spain. Antimicrob Agents Chemother. 2017 Oct 24;61(11):e01589-17
NO This work was supported by Plan Nacional de I D i 2013-2016 and Instituto deSalud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía, Industria y Competitividad, Spanish Network for Research in Infectious Diseases (grants REIPI RD16/0016/0002, RD16/0016/0004 RD16/0016/0005, RD16/0016/0007, RD16/0016/0008, RD16/0016/0010, and RD16/0016/0015), and grants PI15/00088 (PI AO) and PI13/00984 (PI JPH) cofinanced by European Development Regional Fund (ERDF) “A way to achieve Europe,” Operative program Intelligent Growth2014-2020.
DS RISalud
RD Apr 12, 2025